A bipartisan group of senators is working to alleviate the financial burden of insulin for millions of Americans living with diabetes. The proposed legislation seeks to cap the cost of the life-saving drug, building on previous efforts to address affordability.

The High Cost of Insulin

For individuals like two-year-old Bain Brandon of Mississippi, who has Type 1 diabetes, insulin is not just important – it’s essential for survival. Even with health insurance, the cost remains significant. Bain’s parents recently paid $194 for a one-month supply of vials and a three-month supply of backup pens, according to his mother, Marlee Brandon.

Impact on Families

Marlee Brandon expressed concern about the future, stating, “One day, Bain will be an adult, and he won’t be able to be on our insurance anymore.” She highlighted a lack of awareness regarding the ongoing expense of managing diabetes. Breana Glover, a 23-year-old from Houston, moved to Texas specifically to lower living expenses and better afford her diabetes care, including insulin.

The Proposed Legislation

The new bill, known as the INSULIN Act, aims to cap insulin costs. Previous attempts to pass similar legislation, including a House-passed bill in 2022 to cap insulin at $35 per month for those with private insurance, failed to gain Senate approval. A similar provision was also removed from the Inflation Reduction Act due to Republican opposition.

Industry Response and Challenges

Major insulin manufacturers – Eli Lilly, Sanofi, and Novo Nordisk – have taken steps to reduce costs through various programs, including list price cuts and affordability initiatives. However, approximately 57% of Americans with private insurance have self-insured plans that are not subject to state cost-cap regulations. Pharmaceutical trade association PhRMA points to pharmacy benefit managers and insurers as contributing to affordability barriers.

Advocacy and Hope

Advocates believe the bill will particularly benefit young adults who often struggle to obtain affordable health insurance. Manny Hernandez, CEO of The Diabetes Link, expressed optimism after meetings with Republican members of Congress but acknowledged the potential for competing priorities to derail the legislation. Dr. Leslie Eiland of the University of Nebraska Medical Center emphasized the need to simplify access to cost savings for patients.

Despite past setbacks, advocates remain hopeful that this bipartisan effort will succeed in lowering insulin costs and improving access to this vital medication for millions of Americans.